By Tesse Muldoon Myositis has had a profound impact on my life in many ways. After seven years of odd skin rashes and a number of other autoimmune conditions, I was diagnosed with cancer-associated dermatomyositis in 2017, and it drastically changed my path. Before becoming disabled, I was a certified nursing assistant (CNA) and was…
Continue Reading
On Monday, February 10, 2025, Rich DeAugustinis, Vice Chair of TMA’s Board of Directors, testified to the Georgia Senate Committee on Health and Human Services in support of the Georgia Hope for Patients Act (S.B. 72). This proposed legislation, sponsored by Georgia Senator Matt Brass, will allow patients who have severely debilitating or life-threatening illnesses to…
Continue Reading
By Paula Eichenbrenner, TMA Executive Director and Laurie Boyer, TMA Board of Directors Chair At TMA, we believe research is the key to better treatments and a brighter future for those living with myositis. Our mission includes an important commitment to “fund innovative myositis research.” In fact, TMA has invested nearly $10 million into research…
Continue Reading
Compared to current therapies, chimeric antigen receptor (CAR) T cell therapy can not just suppress the immune system, but partially reset it, interrupting the loop of chronic inflammation and tissue damage caused by autoimmune conditions like myositis. At the International Annual Patient Conference hosted by TMA on September 6-8, 2024, in Baltimore, Maryland, Dr. Maximillian…
Continue Reading
The Myositis Association (TMA) recognizes that best hope for a cure for myositis diseases lies in research. Since 2002, TMA’s annual research grants program has approved 68 projects totaling nearly $8.2 million to study the underlying causes and natural progression of myositis, develop better treatments and more effective therapies, and ultimately to create a cure for…
Continue Reading